Completed PHASE2 INTERVENTIONAL 2-arm NCT00000815

A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group

Sponsor: Merck Sharp & Dohme LLC

Updated 9 times since 2017 Last updated: Oct 27, 2021 Completion: Aug 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00000815, this PHASE2 trial focuses on HIV Infections and Measles and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2022 — Jul 2024 [monthly]

Completed PHASE2
Nov 2021 — Jun 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Nov 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Bayamón, Puerto Rico , Birmingham, United States , Boston, United States , Charleston, United States , Chicago, United States , Detroit, United States and 24 more locations